Bentley Pharmaceuticals to Release Fourth-Quarter 2007 Financial Results on March 13, 2008
29 Febrero 2008 - 9:25AM
Business Wire
Bentley Pharmaceuticals, Inc. (NYSE: BNT), a specialty
pharmaceutical company, today announced that management will host a
conference call to discuss fourth-quarter and year-end 2007
financial results on Thursday, March 13, 2008, at 10:00 a.m. (ET).
On the call, the Company will also provide an update on the ongoing
process of separating its drug delivery business from its generic
pharmaceuticals business. Bentley will release its results for the
three months and full year ended December 31, 2007, before the
market opens on that day. To participate on the live call, please
dial (888) 332-7254 or (973) 582-2856 for international callers.
The access code for the call is 33823748. The conference call will
also be webcast live and may be accessed via Bentley�s website,
www.bentleypharm.com. A telephone replay will be available for 30
days by dialing (800) 642-1687 or (706) 645-9291 for international
callers. Please reference reservation number 33823748. A replay of
the conference call also will be available on Bentley�s website for
30 days. Bentley Pharmaceuticals, Inc. is a specialty
pharmaceutical company focused on advanced drug delivery
technologies and generic pharmaceutical products. Bentley�s
proprietary drug delivery technologies enhance the absorption of
pharmaceutical compounds across various membranes. Bentley plans to
spin off its drug delivery business as an independent, publicly
traded company. Its newly formed subsidiary, CPEX Pharmaceuticals,
Inc., has filed an initial registration statement on Form 10 with
the Securities and Exchange Commission (SEC) in furtherance of this
plan. Completion of the proposed spin-off is subject to numerous
conditions, including final approval by Bentley�s Board of
Directors and the effectiveness of the registration statement on
Form 10, which is subject to review by the SEC. Bentley�s generic
pharmaceuticals business manufactures and markets a growing
portfolio of generic and branded generic products in Europe for the
treatment of cardiovascular, gastrointestinal, infectious and
central nervous system diseases through its subsidiaries --
Laboratorios Belmac, Laboratorios Davur, Laboratorios Rimafar and
Bentley Pharmaceuticals Ireland. Bentley also manufactures and
markets active pharmaceutical ingredients through its subsidiary,
Bentley API. Additional information regarding Bentley
Pharmaceuticals may be obtained through Bentley�s website at
www.bentleypharm.com.
Brookfield Wealth Soluti... (NYSE:BNT)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024
Brookfield Wealth Soluti... (NYSE:BNT)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024
Real-Time news about Brookfield Wealth Solutions Ltd (New York Stock Exchange): 0 recent articles
Más de Bentley Pharmaceuticals, Inc. Artículos de Noticias